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he methylxanthine, caffeine, is the most widely
used psychoactive substance in the world. Most of the
caffeine consumed comes from dietary sources such as
coffee, tea, soft drinks, and chocolate. The content of caf-
feine of these food items ranges from 70 to 220 mg/150
mL for coffee to 30 to 40 mg/150 mL for tea, 15-35
mg/150 mL for cola drinks, and 4 mg/150 mL for choco-
late drinks.
1 World caffeine consumption from all
sources can be estimated as 76 mg/person/day, but
reaches about 220 mg/day in the United States and
Canada, and more than 400 mg/person/day in Sweden
and Finland.
1,2
Caffeine acts as a psychostimulant and exerts numerous
effects on the brain. These include stimulant effects on
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Caffeine is not considered addictive, and in animals it does not trigger metabolic increases or dopamine release in brain
areas involved in reinforcement and reward. Our objective was to measure caffeine effects on cerebral perfusion in
humans using single photon emission computed tomography, with a specific focus on areas of reinforcement and reward.
Two groups of nonsmoking subjects were studied, one with a low (8 subjects) and one with a high (6 subjects) daily cof-
fee consumption. The subjects ingested 3 mg/kg caffeine or placebo in a raspberry-tasting drink, and scans were per-
formed 45 min after ingestion. A control group of 12 healthy volunteers receiving no drink was also studied. Caffeine
consumption led to a generalized, statistically nonsignificant perfusion decrease of 6% to 8%, comparable in low and
high consumers. Compared with controls, low consumers displayed neuronal activation bilaterally in inferior frontal gyrus-
anterior insular cortex and uncus, left internal parietal cortex, right lingual gyrus, and cerebellum. In high consumers,
brain activation occurred bilaterally only in hypothalamus. Thus, on a background of widespread low-amplitude perfu-
sion decrease, caffeine activates a few regions mainly involved in the control of vigilance, anxiety, and cardiovascular reg-
ulation, but does not affect areas involved in reinforcing and reward.  
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of anxiety, effects on vigilance and sleep, on information
processing and performance.
3 In the periphery, the
effects of coffee/caffeine have been studied, but at mod-
erate doses, they do not appear to exert harmful effects
on cardiovascular function.
4
The issue of a possible dependence on caffeine has been
debated for many years.
5-8 Caffeine acts as a mild rein-
forcer (ie, maintaining its self-administration or being
preferentially chosen over placebo), although not con-
sistently in both humans and animals.
6 In humans, the
widely recognized behavioral stimulant and mildly rein-
forcing properties of caffeine are probably responsible
for the maintenance of caffeine self-administration.
7,9
The possible physical dependence to the methyxanthine
has been considered for about two decades,
5,9,10 but
appears to be quite low compared with common drugs
of abuse, such as cocaine, amphetamine, morphine, and
nicotine. 
The critical role of the mesolimbic dopamine system has
been emphasized as underlying drug dependence.
11,12
This system consists of the dopaminergic neurons origi-
nating in the ventral tegmental area, projecting to the
nucleus accumbens, and ending in the frontal and pre-
frontal cortex. Drugs of abuse selectively activate the
shell of the nucleus accumbens, which belongs to the
mesolimbic dopaminergic system and is currently rec-
ognized as a critical target of drugs of abuse.
13-15The shell
of the nucleus accumbens plays a role in emotion, moti-
vation, and reward functions. The laterodorsal core part
of the nucleus accumbens regulates somatomotor func-
tions. The drugs of abuse specifically increase dopamine
release and functional activity (glucose utilization and
blood flow) in the shell of the nucleus accumbens with-
out affecting the core of the nucleus.
13,14 These drug-
induced changes in the shell of the nucleus accumbens
have been hypothesized to relate to the general abuse
liability of these drugs independently from their specific
mechanism of action.
12
In a previous study, we investigated the effects of 1 to
10 mg/kg caffeine on local cerebral glucose utilization
in rats. We showed that 1 to 5 mg/kg caffeine in the rat
(70 to 350 mg for a 70-kg individual) which are in the
range of normal human daily consumption
1,2 failed to
increase metabolic levels in the shell of the nucleus
accumbens.
15 Likewise, caffeine did not induce a release
of dopamine in the shell of the nucleus accumbens
when injected over a large spectrum of doses ranging
from 0.5 to 30.0 mg/kg.
16,17 However, the high dose of 10
mg/kg caffeine in rats, no longer representative of
human consumption—7 large cups of coffee in one sit-
ting—led to unspecific metabolic increases in the shell
and the core of the nucleus accumbens, together with
the activation of most motor, limbic, thalamic, and cor-
tical regions.
15
The objective of the present study was to extend these
approaches to the human situation and to measure the
effects of caffeine on cerebral perfusion in human sub-
jects using single photon emission computed tomogra-
phy (SPECT). We measured caffeine-induced perfusion
changes in a large number of brain areas, including the
areas involved in the circuit of dependence and reward,
mainly the nucleus accumbens and prefrontal cortex.
Moreover, two groups of subjects were studied, one with
a low daily coffee consumption and one with a high daily
coffee consumption. They were compared with a control
group not exposed to any drink to account for the




A total number of 26 normal human subjects (10 men
and 16 women), ranging in age from 19 to 47 (mean age,
29.9 + 7.9 years; median, 28 years) with no history or
clinical evidence of medical, neurological, or psychiatric
disease participated in this study. The subjects were
recruited among the healthy nonsmoking population,
and met the following additional criteria: no night shift-
work, no use of any medication except for birth control,
and no report of any history of alcohol or drug abuse. To
exclude any morphological abnormality, cerebral mag-
netic resonance imaging (MRI) was performed in all
cases. All subjects gave their informed written consent
before the study, which was approved by the local ethi-
cal committee. 
Caffeine groups
Within the caffeine groups, the first subgroup of eight
subjects consisted of a population of very low caffeine
consumers or abstainers (0 to 1 cup of coffee per day, ie,
less than 100 mg/day, low-consumption, LC group); the
second one included six subjects who consumed elevated
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PAGES_11_AG_1009_BA.qxd:DCNS#45  9/06/10  10:27  Page 256quantities of coffee (more than 4 cups per day, ie, over
500 mg/day) and reported feeling “dependent” on cof-
fee (high-consumption, HC group). This was only based
on the subjects’ own feelings and not on any DSM-IV
criteria. The subjects were told that they were entering
a study on the effects of caffeine on cerebral circulation,
but were not informed about the exact purpose of the
study, ie, the study of the specific effect of caffeine on the
brain areas involved in drug dependence. 
The subjects were asked to observe a 12-hour abstinence
from caffeine-containing foods and beverages prior to
the measurement of cerebral blood flow. Blood samples
were taken at arrival at the hospital to reinforce com-
pliance. The subjects ingested 3 mg/kg body weight caf-
feine or a placebo in a raspberry-tasting drink. The
drinks were prepared by the pharmacy of the University
Hospitals and were administered in a double-blind, ran-
domized, counterbalanced design. The blood pressure
and heart rate were measured and the mood and anxi-
ety profiles of the subjects assessed with a specific ques-
tionnaire before and after caffeine ingestion. The ques-
tionnaire used was the State-Trait Anxiety Inventory
(STAI) for adults which is the most widely used self-
report measure of tension and anxiety. 
Control group
To allow group analysis and evaluation of the inter- and
intraindividual variations of cerebral perfusion, a con-
trol group of 12 healthy volunteers was included in the
study. Within this group of twelve healthy volunteers
(low consumers of 0 to 2 cups of coffee daily) not receiv-
ing any drink before the two SPECT examinations, eight
and six were randomly selected for comparison with the
LC and HC caffeine group, respectively, while the whole
caffeine-consuming group was compared with the total-
ity of the control group.
SPECT procedure
The caffeine groups subjects were subjected to two sep-
arate morning examinations upon arrival at the hospi-
tal: (i) one SPECT study after the placebo beverage;
and (ii) one SPECT study after the caffeine containing
beverage. The two beverages were given on two differ-
ent days at 7-day interval, in a double-blind randomized
counterbalanced design. Upon arrival at the clinic, the
subjects were invited to relax in a comfortable armchair
in a quiet and pleasant room. A venous catheter for
tracer injection was immediately inserted into the left
arm, and a first blood sample was taken to measure caf-
feine levels to check for compliance to 12 h caffeine
abstinence. Heart rate and blood pressure measure-
ments were then performed and the subjects filled in
the STAI questionnaire. Then, subjects received the caf-
feine or placebo drink and were asked to rest in the
same surrounding for 45 min. This time was chosen
since caffeine reaches peak values in the brain between
45 and 60 min postingestion.
3 Thereafter, the subjects
underwent the same procedure for the measurement of
plasma caffeine levels, cardiovascular parameters, and
filled in the STAI questionnaire again. Immediately
afterwards, the tracer, 640-925 MBq
99mTc-ethyl cys-
teinate dimer (ECD, Neurolite, Bristol-Myers Squibb
Medical Imaging), was injected into the already inserted
venous catheter. The subjects were not allowed to read,
write, or talk for 5 min, including the fixation period of
the radiotracer.
The control group subjects were also subjected to two
separate morning SPECT examinations at 7-day inter-
vals, in the same conditions, without any beverage. This
procedure was used to evaluate the intrasubject vari-
ability between two examinations and to avoid the con-
sequences of variable spontaneous mental activity
and/or possible perfusion changes induced by the stress-
ful environment related to SPECT examination.
SPECT imaging studies were realized with a low-energy,
high-resolution, double-head camera (Helix, Elscint).
The camera was operated in the “stop and shoot” mode,
with acquisitions at 3° intervals and a total acquisition
time of 25 min (120 projections, 642 matrix). The total
number of counts was superior to 6 million. Slices were
reconstructed by filtered back-projection using a Metz
filter (FWMH of 8 mm). Slices were acquired 30 min
after the injection of ECD. 
Image analysis and statistics
Images were realigned with each other using affine algo-
rithm in MEDIMAX software,
18 transformed into the
standard anatomic space corresponding to the atlas of
Talairach, and normalized in statistical parametric map-
ping software (SPM2, Wellcome Department of Imaging
Neuroscience, London) using MATLAB (Mathworks
Inc, Massachusetts) for calculations and image matrix
manipulations.
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tical analysis was performed by multigroup analysis with
SPM2. A voxel-by-voxel comparison according to the
general linear model and I statistics was used to calcu-
late the differences in cerebral perfusion between the
two conditions (caffeine vs placebo) of caffeine groups
and the differences between two conditions (rest vs rest)
of the control group (LC group vs control group, HC
group vs control group, and LC + HC groups vs control
group). The resulting statistical parametric map was sub-
sequently used to assign probability values (to voxels
and clusters), which were corrected for multiple com-
parisons applied for the whole brain. Significant differ-
ences were defined at a corrected value of P≤0.001 and




Two groups of subjects were studied, including eight sub-
jects (seven females and one male) and seven subjects
(two females and five males) belonging to the LC and
HC groups, respectively (Table I). All clinical data includ-
ing age, arterial blood pressure, heart rate, electrocardio-
graphic recording, and other current physiological para-
meters (plasma potassium level and hepatic enzyme
activities) were in the physiological range and identical
in both groups. None of these parameters was signifi-
cantly affected by caffeine or placebo. In addition, the
clinical surroundings had no significant influence on anx-
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Low consumption  Heavy consumption
(0-1 cup/day) N = 8 (>4 cups/day) N = 6
Baseline data Age (y) 27.6 ± 6.1 30.0 ± 5.1
Arterial BP (mm Hg)
Systolic 109.5 ± 13.3 115.1 ± 10.6
Diastolic 63.1 ± 4.5 64.5 ± 5.9
Heart rate (beats/min) 70.6 ± 4.8 68.1 ± 8.2
Placebo Arterial BP (mm Hg)
Systolic before placebo 118.1 ± 11.3 117.1 ± 12.5
Systolic after SPECT 117.5 ± 20.5 115.7 ± 12.7
Arterial BP (mm Hg)
Diastolic before placebo 75.6 ± 9.8 71.3 ± 13.6
Diastolic after SPECT 77.1 ± 12.5 75.7 ± 12.7
Heart rate (beats/min)
before placebo 78.0 ± 9.0 69.1 ± 10.8
after SPECT 74.0 ± 10.7 70.9 ± 9.2
Plasma caffeine level (mg/L)
before placebo 0.28 ± 0.24 0.21 ± 0.15
after SPECT 0.25 ± 0.27 0.14 ± 0.13
Caffeine Arterial BP (mm Hg)
Systolic before caffeine 115.0 ± 7.6 120.0 ± 14.1
Systolic after SPECT 116.3 ± 13.0 125.0 ± 18.9
Arterial BP (mm Hg)
Diastolic before caffeine 69.4 ± 6.8 77.1 ± 12.5
Diastolic after SPECT 68.8 ± 9.9 77.1 ± 17.0
Heart rate (beats/min)
before caffeine 73.5 ± 9.6 69.1 ± 10.5
after SPECT 71.3 ± 8.9 64.6 ± 8.8
Plasma caffeine level (mg/L)
before caffeine 0.20 ± 0.14 1.64 ± 0.80
after SPECT 0.16 ± 0.12 2.15 ± 1.06
Table I. Clinical data of the subjects undergoing SPECT examinations for the effects of caffeine on cerebral blood flow.
PAGES_11_AG_1009_BA.qxd:DCNS#45  9/06/10  10:27  Page 258iety levels, as assessed upon arrival, and neither did the
dose of caffeine ingested and the insertion of the catheter
for ECD injection, as assessed 45 min later. Subjects had
a tendency to feel more alert after the ingestion of the
caffeine-containing drink. The low level of caffeine
before SPECT analysis confirmed that the patients had
omitted the methylxanthine from their food and bever-
age for 12 h. Circulating levels of caffeine were increased
by a factor of 8 to 13 at about 1 h after caffeine ingestion.
SPECT data
The consumption of caffeine led to a generalized
decrease in perfusion levels of 6% to 8% which was of
similar amplitude in both LC and HC groups (Table II).
Compared with intraindividual variations of control sub-
jects, these changes were not statistically significant. 
On the other hand, discrete perfusion increases corre-
sponding to specific neuronal activation were found in
specific regions. Indeed, when the LC caffeine group was
compared with the control group (Figure 1), increases in
perfusion occurred bilaterally in the inferior frontal
gyrus-anterior insular cortex (predominantly on the
right side) and in the uncus, on the left side in the inter-
nal parietal cortex, on the right side in the lingual gyrus
and cerebellum. In the HC group compared with the
control group, perfusion increases were located bilater-
ally in hypothalamus. When both caffeine groups were
pooled and compared with the whole control group, sig-
nificant perfusion increases occurred bilaterally in the
inferior frontal gyrus-anterior insula, hypothalamus,
right cerebellum, and left uncus (Figure 1).
Discussion
The main findings of this study were the lack of signifi-
cant differences in perfusion between caffeine-exposed
subjects and controls, whether they were HC or LC, the
lack of effects of the methylxanthine on the areas of
reinforcing and reward and only very discrete changes
in perfusion in areas mediating mainly anxiety, attention
and vigilance, and cardiovascular function.
The vasoconstrictive properties of caffeine in the brain
have been known for a long time, and caffeine has been
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Low consumption (0-1 cup/day) n = 8 Heavy consumption (>4 cups/day) n = 6 Student’s t-test
Frontal cortex -6% -6% NS
Median cingular gyrus 0 -6% NS
Anterior insula  -7% -7% NS
Amygdala and temporal lobe -6% -8% NS
Thalamus - hypothalamus -6% -6% NS
Nucleus accumbens 0 0% NS
Vermis 0 -8% NS
Table II. Caffeine-induced changes in cerebral perfusion calculated as follows: (SPECT CAFFEINE - SPECT PLACEBO) / SPECT PLACEBO using SISCOM.
Figure 1. Caffeine-induced perfusion changes superimposed on transax-
ial slices of a standard MRI surface: left column: Low con-
sumption (LC) group (n=8) vs control group (n=8); middle col-
umn: High consumption (HC) group (n=6) vs control group
(n=6); right column: LC+HC group (n=14) vs control group
(n=12).
LC vs control HC vs control LC+HC vs control
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19-23
Previous studies used the 133Xe-xenon inhalation tech-
nique,
22 positron emission tomography,
19 inversion recov-
ery perfusion MR technique [20] and blood oxygenation
level-dependent (BOLD) signal intensity changes in
functional MRI (fMRI).
22,23 Recent papers studied the
effects of caffeine on cerebral circulation since caffeine
ingestion might be a source of errors in functional brain
imaging experiments.
20,21,23
The present study showed a 6% to 8% statistically non-
significant caffeine-induced decrease in perfusion.
Several other studies reported caffeine-induced cerebral
blood flow decreases ranging from 3.4% to 18%
19,20,22,24,25
but not consistently in all subjects.
22The reasons for the
discrepancies may have various origins. First, the hemo-
dynamic response measured by different techniques
(cerebral blood flow, BOLD contrast, or perfusion
changes) is not directly comparable. Second, in most if
not all studies, the same dose of caffeine was given to the
subjects independently of body weight. Conversely, in
the present study, the dose of caffeine ingested was
adjusted to body weight, ie, 3 mg/kg. The third factor dif-
fering amongst the studies is the period of abstinence
from caffeine. The latter was similar to the one applied
here, ie, about 12 h in several studies,
19,23 very short, 2 to
3 hours in other studies,
22,24 or much longer, ie, 30
hours.
20,21The period of abstinence may be an important
factor in the effect of caffeine on cerebral blood flow,
and has been a matter of concern in imaging studies over
the last few years.
20,21 Indeed, the cerebral blood flow
rates and velocities are increased during the withdrawal
state, mainly in high users
20,26 and go back to baseline val-
ues after about 2 h.
26 Therefore the widespread lack of
significance in the perfusion values recorded in the pre-
sent study with and without caffeine may partly reflect
the withdrawal state induced by the overnight caffeine
deprivation imposed on the subjects. On the other hand,
the discrete changes recorded in some brain areas after
caffeine indicate the specific changes due to the methylx-
anthine.
In the present study, on a background of widespread sta-
tistically nonsignificant perfusion decrease, discrete
increases in perfusion corresponding to specific neuronal
activation could be identified. Brain activation was
mostly seen in the LC group. In this group, significant
activation was recorded in regions known to mediate
anxiety like the inferior frontal gyrus-anterior insular cor-
tex, the uncus, the lingual gyrus, and the cerebellum.
27,28
Simultaneously, many other regions involved in the reg-
ulation of anxiety levels, such as the amygdala, cingulate
and orbitofrontal cortex, thalamus, and striatum, were not
activated by caffeine. The inferior frontal gyrus-anterior
insular cortex seems to play a role in anticipating aver-
sive stimuli and in anxiety and emotion regulation.
29 Its
activation was observed in different anticipatory anxiety
induction protocols,
30-32 and was totally different from the
claustrum-posterior insular cortex activation observed in
pharmacologically induced panic attacks with cardiovas-
cular and visceral symptomatology.
32-34 Caffeine is known
to be anxiogenic, at low doses in a subset of individuals
and at quite large doses in most of the population.
35The
activation recorded only in a limited number of areas
may reflect the fact that the subjects did not report
increased anxiety after ingestion of the caffeinated drink.
They could also imply that caffeine may specifically act
at some given steps of the anxiety process, for example,
at the anterior insular cortex for integration of internal
state, parietal cortex for spatially specific associations, but
does not reach, at this dose, the sensory-motor integra-
tion in thalamus and the initiation of action—since there
is no defensive action required—depending on the ante-
rior cingulate cortex.
28,36
Brain activation was observed in the internal parietal
cortex of LC subjects and in the hypothalamus of HC
subjects. These activations relate to changes in vigilance
and attention. The parietal cortex is critical for attention
and spatial updating. It is involved in visual representa-
tions of space in an eye-centered coordinate frame, and
in providing a signal for directing the eyes towards these
objects.
28,37The hypothalamus mediates many vegetative
functions as well as attention and vigilance. In our expe-
rience, hypothalamic activations were often associated
with changes in attention and vigilance. These activations
are in line with the known effects of caffeine on vigi-
lance. Indeed, the pattern of consumption of caffeine
throughout the day shows that caffeine is mostly con-
sumed to increase the level of vigilance,
35 and caffeine is
well known to impair sleep.
3,38 Likewise, caffeine focuses
available attention and energy on the task to complete,
mostly by limiting distracting external stimuli.
39
Finally, the anterior insular cortex, which was activated
by caffeine, regulates cardiovascular function and respi-
ratory rhythms. Numerous epidemiologic studies have
focused on the effects of coffee and caffeine on cardio-
vascular risk, cholesterol, and blood pressure (for review
see ref 40). The data currently available indicate that a
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moderate caffeine intake does not adversely affect car-
diovascular function. However, a recent meta-analysis
on the relationship between coffee, caffeine, and blood
pressure reported that caffeine consumption increases
blood pressure by a mean value of 4.2 mm for systolic
and 2.0 mm Hg for diastolic blood pressure.
41 In the pre-
sent study, the values of systolic blood pressure slightly
increased after caffeine, especially in the HC group, but
because of the large interindividual variability, this slight
change was not significant. In the present study, the main
difference in caffeine-induced brain activation between
LC and HC subjects was the involvement of hypothala-
mus which was the single region affected in HC, while
perfusion was not affected in hypothalamus when the
same amount of caffeine was given to LC. When both
groups were pooled, the caffeine-induced brain activa-
tion was significant in all areas involved in the two
groups.
In the present study, we did not record any brain activa-
tion or inhibition in the different components of the
brain circuit of dependence. In the presurgical follow-
up of a 20-year-old male epileptic patient with right tem-
poral lobe epilepsy and seizures induced by compulsive
smoking, we were incidentally able to show that nicotine
induced clear focal brain activation in the nucleus
accumbens, the key area involved in addiction and
reward, while caffeine (3.5 mg/kg) did not induce change
in brain activation in the nucleus accumbens
(Marescaux, Namer, and Nehlig, unpublished data).
Therefore, these earlier data plus the present data reflect
that caffeine at doses representing about two cups of
coffee in one sitting does not activate the circuit of
dependence and reward and especially not the main tar-
get area, the nucleus accumbens.
10-12This lack of effect is
present both in light and heavy coffee drinkers who had
claimed that they felt “dependent” on coffee. This data
is in agreement with our previous data on rats in which
the doses of 2.5 and 5.0 mg/kg also failed to activate the
circuit of dependence and reward.
15 It is also in good
agreement with recent reviews reporting that caffeine
acts as a mild stimulant that is able to restore mental
alertness and wakefulness, mainly in situations with low
alertness level.
8,42 Therefore, caffeine appears to be dif-
ferent from drugs of dependence like cocaine, amphet-
amine, morphine, and nicotine, and does not fulfil the
common criteria or the scientific definitions to be con-
sidered an addictive substance.
42 ❏
Acknowledgements: This study was supported by a grant from PEC-ISIC,
Vevey (Switzerland), the Hôpitaux Universitaires de Strasbourg and
University Louis Pasteur and was approved by the Alsace ethics committee
(n° 00/80, 12.09.2000 and n° 02/35, 09.04.2002). All subjects gave their writ-
ten informed consent prior to participation.
The assistance of the Centre d’Investigations Cliniques (CIC) and pharmacy
staff of the Hôpitaux Universitaires de Strasbourg is gratefully acknowl-
edged. We also wish to thank A. Mathis and G. Erb for valuable advice. 
REFERENCES
1. Debry G, ed. Coffee and Health. London, UK: John Libbey; 1994.
2. Barone JJ, Roberts HR. Caffeine consumption. Food Chem Toxicol.
1996;34:119-126.
3. Fredholm BB, Bättig K, Holmen J, Nehlig A, Zvartau E. Actions of caf-
feine in the brain with special reference to factors that contribute to its
widespread use. Pharmacol Rev. 1999;51:83-133.
4. Higdon JV, Frei B. Coffee and health: a review of recent human
research. Crit Rev Food Sci Nutr. 2006;46:101-123.
5. Griffiths RR, Woodson PP. Caffeine physical dependence, a review of
human and laboratory animal studies. Psychopharmacology. 1988;94:437-
451.
6. Juliano L. M, Griffiths RR, A critical review of caffeine withdrawal:
empirical validation of symptoms and signs, incidence, severity, and associ-
ated features, Psychopharmacology. 2004;176:1-29. 
7. Nehlig A, Are we dependent on coffee and caffeine? A review on
human and animal data. Neurosci Biobehav Rev. 1999;23:563-576.
8. Nehlig A. Are we dependent on coffee and caffeine: an update. in
Nehlig A, ed. Coffee, Tea, Chocolate and the Brain. Boca Raton, FL: CRC Press;
2004:133-146. 
9. Griffiths RR, Mumford GK. Caffeine reinforcement, discrimination, tol-
erance and physical dependence in laboratory animals and humans. In:
Schuster, CR, Kuhar MJ, eds. Handbook of Experimental Pharmacology. Vol 118.
Heidelberg, Germany: Springer Verlag; 1996:315-341.
10. Koob GF. Drugs of abuse: anatomy, pharmacology and function of
reward pathways. Trends Pharmacol Sci. 1992;13:177-184. 
11. Self DW, Nestler EJ. Molecular mechanisms of drug reinforcement and
addiction. Annu Rev Neurosci. 1995;18:463-495.
12. Di Chiara G. The role of dopamine in drug abuse viewed from the per-
spective of its role in motivation. Drug Alcohol Depend. 1995;38:95-137.
13. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and
amphetamine preferentially increase extracellular dopamine in the "shell"
as compared with the "core" of the rat nucleus accumbens. Proc Natl Acad
Sci U S A. 1995;92:12304-12308. 
14. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the
nucleus accumbens and similarity to those of addictive drugs. Nature.
1996;382:255-257. 
15. Nehlig A, Boyet S. Dose-response study of caffeine effects on cerebral
functional activity with a specific focus on dependence. Brain Res.
2000;858:71-77.
16. Acquas E, Tanda G, Di Chiara G. Differential effects of caffeine on
dopamine and acetylcholine transmission in brain areas of drug-naive and
caffeine-pretreated rats. Neuropsychopharmacology. 2002;27:182-193.
17. De Luca MA, Bassareo V, Bauer A, Di Chiara G. Caffeine and accumbens
shell dopamine. J Neurochem. 2007;103:157-163.
18. Nikou C, Heitz F, Armspach JP, Namer IJ, Grucker D. Registration of
MR/MR and MR/SPECT brain images by fast stochastic optimization of robust
voxel similarity measures. NeuroImage. 1998;8:30-43.
19. Cameron OG, Modell JG, Hariharan M. Caffeine and human cerebral
blood flow: a positron emission tomography study. Life Sci. 1990;47:1141-
1146.
20. Field AS, Laurienti PJ, Yen YF, Burdette JH, Moody DM. Dietary caffeine
consumption and withdrawal: confounding variables in quantitative cere-
bral perfusion studies? Radiology. 2003;227:129-135.
PAGES_11_AG_1009_BA.qxd:DCNS#45  9/06/10  10:27  Page 261Free paper
262
Evaluación con SPECT de la activación 
cerebral inducida por cafeína: ausencia 
de efecto en áreas involucradas en la 
dependencia 
No se considera que la cafeína sea adictiva y en ani-
males no provoca  aumento del metabolismo ni
liberación de dopamina en las áreas que participan
en los mecanismos de refuerzo y recompensa.
Nuestros objetivos fueron medir los efectos de la
cafeína en la perfusión cerebral utilizando la tomo-
grafía computada de emisión de fotón único con
un foco específico en las áreas de refuerzo y recom-
pensa. Se estudiaron dos grupos de sujetos no
fumadores, uno con bajo consumo diario de café (8
sujetos) y otro con alto consumo (6 sujetos). Los
sujetos ingirieron 3mg/kg de cafeína o placebo en
una bebida con sabor a frambuesa y los escáners se
realizaron 45 minutos post-ingesta. También se
estudió un grupo control de 12 voluntarios sanos
que no recibió ninguna bebida. El consumo de cafe-
ína determinó una disminución generalizada del
6% al 8% de la perfusión, sin significación estadís-
tica, comparable tanto en los sujetos con bajo como
con alto consumo. En comparación con los contro-
les, los sujetos de bajo consumo mostraron activi-
dad neuronal bilateral en el giro frontal inferior-
corteza insular anterior  y en el uncus, la corteza
parietal interna izquierda, el giro lingual derecho y
el cerebelo. En los sujetos de alto consumo la acti-
vación cerebral ocurrió bilateralmente sólo en el
hipotálamo. Por lo tanto, la cafeína -aunque pro-
voca de fondo una extensa disminución de la per-
fusión de baja amplitud- activa unas pocas regiones
involucradas principalmente en el control de la vigi-
lancia, la ansiedad y la regulación cardiovascular, sin
afectar áreas que participan en el refuerzo y la
recompensa. 
Évaluation par SPECT de l’activité cérébrale
induite par la caféine : aucun effet sur les
aires impliquées dans la dépendance
La caféine n’engendre pas de dépendance et ne
déclenche pas d’augmentation du métabolisme ou
de libération de dopamine dans les aires cérébrales
impliquées dans le renforcement ou la récompense
chez les animaux. Notre but était de mesurer les
effets de la caféine sur la perfusion cérébrale
humaine en utilisant la tomographie par émission
monophotonique, en insistant sur les aires du ren-
forcement et de la récompense. Deux groupes de
sujets non fumeurs ont été étudiés, l’un ayant une
faible (8 sujets) et l’autre une forte (6 sujets) con-
sommation quotidienne de café. Les sujets ont pris
3 mg/kg de caféine ou un placebo dans une boisson
au goût de framboise et des scanners ont été réali-
sés 45 min après l’ingestion, un groupe témoin de
12 volontaires sains ne prenant aucune boisson
étant également étudié. La consommation de
caféine a conduit à une réduction généralisée du
débit statistiquement non significative de 6 % à 8 %,
comparable chez les petits ou gros consommateurs.
Les petits consommateurs, par rapport aux témoins,
ont présenté une activation neuronale bilatérale
dans le gyrus frontal inférieur, le cortex insulaire
antérieur et l’uncus, dans le cortex pariétal interne
gauche, le gyrus lingual droit et le cervelet. Chez les
gros consommateurs, l’activation cérébrale est
apparue de façon bilatérale seulement dans l’hy-
pothalamus. Ainsi, sur un fond de diminution éten-
due du débit de faible amplitude, la caféine active-
rait quelques régions principalement impliquées
dans le contrôle de la vigilance, de l’anxiété et de
la régulation cardiovasculaire, mais n’affecterait pas
les aires impliquées dans le renforcement et la
récompense. 
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